The present invention provides amedicament for treating an ocular disease comprising a therapeutically effective amount of a cyclohexanehexol compound of the formula III or IV:wherein X is a cyclohexane ring, wherein R1, R2, R3, R4, R5, and R6 are hydroxyl or at least one of R1, R2, R3, R4, R5, and R6 is independently selected from hydrogen, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, C2-C6alkenyloxy, C3-C10cycloalkyl, C4-C10cycloalkenyl, C3-C10cycloalkoxy, C6-C10aryl, C6-C10aryloxy, C6-C10aryl-C1-C3alkoxy, C6-C10aroyl, C6-C10heteroaryl, C3-C10heterocyclic, C1-C6acyl, C1-C6acyloxy, -NH2, -NHR7, -NR7R8, =NR7, -S(O)2R7, -SH, -SO3H, nitro, cyano, halo, haloalkyl, haloalkoxy, hydroxyalkyl, -Si(R7)3, -OSi(R7)3, -CO2H, -CO2R7, oxo, -PO3H, -NHC(O)R7, -C(O)NH2, -C(O)NHR7, -C(O)NR7R8, -NHS(O)2R7, -S(O)2NH2, -S(O)2NHR7, and -S(O)2NR7R8 wherein R7 and R8 are independently selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10aryl C1-C3alkyl, C6-C10 heteroaryl and C3-C10heterocyclic, and at least one of the remainder of R1, R2, R3, R4, R5, or R6 is hydroxyl； or a pharmaceutically acceptable salt thereof.
